Evelo Biosciences is pioneering Oncobiotic™ therapeutics, a new modality in cancer therapy based on the cancer microbiome.
Evelo Biosciences is pioneering Oncobiotic™ therapeutics, a new modality in cancer therapy based on the cancer microbiome.
Evelo Biosciences has built a proprietary discovery, design and development platform based on a deep understanding of cancer associated bacteria and bacterial immune activating factors to develop microbiome-based CAB and BIA™ therapies for cancer.
Evelo Biosciences has built a proprietary discovery, design and development platform based on a deep understanding of cancer associated bacteria and bacterial immune activating factors to develop microbiome-based CAB and BIA™ therapies for cancer.
Oncobiotic™ therapeutics are bacteria-based treatments for cancer that leverage the ability of bacteria to uniquely and powerfully disrupt the metabolic cancer environment, highly influence the immune system, affect the cancer microenvironment, and much more.
Oncobiotic™ therapeutics are bacteria-based treatments for cancer that leverage the ability of bacteria to uniquely and powerfully disrupt the metabolic cancer environment, highly influence the immune system, affect the cancer microenvironment, and much more.
Evelo's Board of Directors combines expertise across industry, academia, drug development and the investment community, unified by the mission to improve the lives of patients.
Evelo's Board of Directors combines expertise across industry, academia, drug development and the investment community, unified by the mission to improve the lives of patients.
620 Memorial Drive | Suite 200 West | Cambridge, MA, 02139 USA
info@evelotx.com
+ 1 (617) 577-0300
620 Memorial Drive | Suite 200 West | Cambridge, MA, 02139 USA
info@evelotx.com
+ 1 (617) 577-0300
